The report covers Retinal Biologics Market Shares and Segments Analysis such as drugs into VEGF-A antagonists and TNF-A inhibitors, targeting conditions like macular degeneration, diabetic retinopathy and uveitis. Distribution channels include hospital, retail and online pharmacies. Geographically North America, Europe, Asia Pacific, Latin America and the Middle East & Africa leads the market. The report offers the value (in USD Billion) for the above segments.
Growth and Trends in the Global Retinal Biologics Market
The global retinal biologics market, valued at approximately USD 23.18 billion in 2023, is projected to reach USD 49.67 billion by 2033, reflecting a robust compound annual growth rate (CAGR) of 7.92% from 2024 to 2033. This growth is primarily driven by the increasing geriatric population.
The market is predominantly led by therapeutic drugs designed for retinal conditions, including diabetic retinopathy and age-related macular degeneration. Retinal biologics encompass a wide range of treatments, such as growth factors, vaccinations, immunological modulators, human blood and plasma products, and monoclonal antibodies. These biologics, derived from biotechnology involving people, animals, or microbes, represent a significant advancement in medical treatments. They include vaccines, blood components, cells, allergy treatments, gene therapies, tissues, and recombinant proteins.
Biological therapies have revolutionized the treatment of retinal diseases, particularly neovascular retinal conditions, significantly improving patient outcomes and contributing to the market’s expansion.
Retinal Biologics Market TOC | Table of Content
Introduction
- Research Objective
- Scope of the Study
- Definition and Taxonomy
Research Methodology
- Research Approach
- Data Sources
- Assumptions
Executive Summary
- Synopsis
- Analyst Recommendations
Market Overview
- Market Dynamics
- Market Drivers
- Market Restraints
- Market Opportunities
- Value Chain Analysis
- Raw Material Sourcing
- Manufacturing Process
- Logistics & Transportation
- Buyer Preferences
- Trends
- Market Trends
- Technological Trends
- Porter’s Five Forces Analysis
- Bargaining Power of Suppliers
- Bargaining Power of Buyers
- Threat of Substitute
- Threat of New Entrants
- Degree of Competition
- PESTLE Analysis for 5 Leading Countries
- Regulatory Framework for Leading Countries/Regions
- Supply Demand Analysis
- Production & Consumption Statistics
- Export Import Statistics
- Price Trend Analysis
Global Retinal Biologics Market Assessment
- Overview
- Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
- VEGF-A Antagonist
- TNF-A Inhibitor
- Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
- Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Region (2021 – 2033)
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
North America Retinal Biologics Market Assessment
- Overview
- North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
- VEGF-A Antagonist
- TNF-A Inhibitor
- North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
- North America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Europe Retinal Biologics Market Assessment
- Overview
- Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
- VEGF-A Antagonist
- TNF-A Inhibitor
- Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
- Europe Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Asia Pacific Retinal Biologics Market Assessment
- Overview
- Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
- VEGF-A Antagonist
- TNF-A Inhibitor
- Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
- Asia Pacific Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Latin America Retinal Biologics Market Assessment
- Overview
- Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
- VEGF-A Antagonist
- TNF-A Inhibitor
- Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
- Latin America Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Middle East & Africa Retinal Biologics Market Assessment
- Overview
- Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Drug Class (2021 – 2033)
- VEGF-A Antagonist
- TNF-A Inhibitor
- Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Indication (2021 – 2033)
- Macular Degeneration
- Diabetic Retinopathy
- Uveitis
- Others
- Middle East & Africa Retinal Biologics Market Size Value (US$) and Volume (Billion Tons), by Distribution Channel (2021 – 2033)
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
Company Profiles
- Santen Pharmaceutical Co., Ltd (Japan)
- Company Overview
- Geographic Footprints
- Financial Performance
- Product Portfolio
- SWOT Analysis
- R&D Efforts
- Recent Developments & Strategic Collaborations
- Product Launch/M&A/Technical Collaboration
- AbbVie Inc. (U.S.)
- Aurobindo Pharma (India)
- Bayer AG (Germany)
- Bayer AG (Germany)
- Fresenius Kabi AG (Germany)
- AstraZeneca (U.K.)
- Teva Pharmaceuticals Industries Ltd. (Israel)
- Sun Pharmaceutical Industries Ltd. (India)
- Merck & Co Inc. (U.S.)
- Boehringer Ingelheim International GmbH. (Germany)
- Amgen Inc. (U.S.)
- Novartis AG (Switzerland)
- Pfizer Inc. (U.S.)
- Kodiak Sciences Inc. (U.S.)
Conclusion & Recommendations
To own our research study instantly, Click here @ https://www.towardshealthcare.com/price/5166
You can place an order or ask any questions, please feel free to contact us at sales@towardshealthcare.com
About Us
Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.
Explore the comprehensive statistics and insights on healthcare industry data and its associated segmentation: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare